Acute Myeloid Leukemia Registry

Conditions

Acute Myeloid Leukemia

Brief summary

All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.

Detailed description

This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey. Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up. All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.

Karakus V, Pinar IE, Iltar U, Yenihayat EM, Polat MG, Celik S, Malkan UY, Cengiz Seval G, Dogan A, Akdeniz A, Ozbalci D, Ince I, Erdem R, Mehtap O, Kirkizlar HO, Kacmaz M, Deveci B, Aykas F, Korkmaz G, Yigit Kaya S, Afacan Ozturk HB, Sevindik OG, Can F, Cekdemir D, Aslan C, Bulbul H, Karabulut ZT, Maral S, Durusoy SS, Demirkan F, Goker H, Ozkalemkas F, Keklik M, Toprak SK, Karatas AF, Atas U, Alacacioglu I, Turkish Society of Hematology-Acute Leukemias Working Group.

2025-10-18

10.3390/jcm14207367

Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project.

Pinar IE, Celik S, Polat MG, Karatas AF, Dogan A, Iltar U, Cengiz Seval G, Malkan UY, Ince I, Yenihayat EM, Akdeniz A, Kacmaz M, Erdem R, Afacan Ozturk HB, Kirkizlar HO, Korkmaz G, Aykas F, Mehtap O, Deveci B, Sevindik OG, Can F, Ozbalci D, Bulbul H, Durusoy SS, Atas U, Keklik M, Toprak SK, Goker H, Demirkan F, Ozkalemkas F, Alacacioglu I, Karakus V, Turkish Society of Hematology-Acute Leukemias Working Group.

2025-10-101 citations

10.1186/s12885-025-14987-z

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Diagnosed as AML after 1 Jan 2020 * Patients signed informed consent form

Exclusion criteria

* Patients under 18 years old

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival	60 months	From diagnosis to exits by any cause

Countries

Turkey (Türkiye)

Contacts

Primary ContactVolkan Karakus, Assoc. Prof.

dr_v_karakus@yahoo.com905057656778

Backup ContactIlker Kurkcu

ilker.kurkcu@sentez-cro.com905326354515

Outcome results